SCHEMBL29244477

SCHEMBL29244477

CC(N)COc1c(Cl)nc(Cl)nc1NCCc1c[nH]c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ SLC2A1 P11166 1/20 0.47
▸ RAD52 P43351 1/20 0.47
▸ HTT P42858 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ GFER P55789 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ IP6K1 Q92551 2/20 0.45
▸ HTR2A P28223 10/20 0.44
▸ HTR1A P08908 9/20 0.44
▸ HTR7 P34969 8/20 0.44
▸ HTR6 P50406 8/20 0.44
▸ DRD2 P14416 7/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ ADRB1 P08588 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29244423 0.90 IP6K1 (0.49) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL29244426 0.90 IP6K1 (0.49) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL29244421 0.90 IP6K1 (0.49) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL31535642 0.90 IP6K1 (0.49) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL30698037 0.90 IP6K1 (0.49) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL31535654 0.88 KMT2A (0.45) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL31535662 0.88 KMT2A (0.45) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL29244529 0.86 KMT2A (0.47) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL30278038 0.86 KMT2A (0.47) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL29244482 0.85 KMT2A (0.50) KMT2APOLBSLC2A1RAD52HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4396191-B1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2026-02-18 — — EP disclosed
US-20250129092-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2025-04-24 — — US disclosed
EP-4396191-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2024-07-10 — — EP disclosed
CN-118076613-A Compounds useful for modulating AhR signaling 捷豹治疗有限公司 2024-05-24 — — CN disclosed
WO-2023033740-A9 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2023-12-28 — — WO disclosed
WO-2023033740-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129092-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING AHR, ARNT, AIPL1 KMT2A 1548/4885POLB 4212/4885SLC2A1 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback